CD19 Positive

12 clinical trials · Condition

Record	Firm	Date
CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma (NCT03579927)	M.D. Anderson Cancer Center	2019-10-03
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (NCT03512405)	City of Hope Medical Center	2019-08-02
CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. (NCT04037566)	Xijing Hospital	2019-08-01
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (NCT04029038)	M.D. Anderson Cancer Center	2019-05-15
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia (NCT03798509)	Hrain Biotechnology Co., Ltd.	2019-03-13
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. (NCT03720457)	Hrain Biotechnology Co., Ltd.	2018-11-13
Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies (NCT03241940)	Stanford University	2017-10-20
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854)	Stanford University	2017-09-01
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia (NCT03275493)	Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd	2017-07-01
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813)	M.D. Anderson Cancer Center	2015-12-16

Track CD19 Positive automatically

Every clearance here is in the API, with alerts when new ones post.